THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (rPARPi) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. The first clinical study for THG-008 in head and neck cancers completed recruitment in May 2019 and data was subsequently published in the following peer-reviewed publication: Schöder et al, 2020 . The first clinical study for THG-008 in brain tumours finished recruiting early this year and the data is now available in the following peer reviewed publication: Young et al, 2020 .

Further Theragnostics sponsored studies and Investigator Initiated Trials are in plan or have completed and will publish in due course.

THG-009 is a novel iodine radiolabelled PARP inhibitor (rPARPi) which will soon enter clinical trials toward the development of this exciting product as a targeted radionuclide therapy.